跳至主要内容
临床试验/NCT02767414
NCT02767414已完成不适用

A Prospective Multi-centre Study of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test Performance Versus Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for the Rapid Detection of Influenza A/B

Ellume Pty Ltd14 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2016年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,500
试验地点
14
主要终点
Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by eLab Flu Test.

研究概览

简要总结

The primary purpose of this study is to validate the sensitivity and specificity of the Respirio Flu Test and the eLab Flu Test in detecting Influenza A as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).

The secondary aims are to:

Validate the sensitivity and specificity of the Respirio Flu Test and the eLab Flu Test in detecting Influenza B as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); Evaluate the correct interpretation of the Respirio Flu Test by subjects with influenza-like symptoms; Evaluate the subjects' satisfaction with the convenience, comfort and ease of use of the Respirio Flu Test.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
1 Year 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subjects aged ≥ 1 year;
  • Rhinorrhea;
  • ≤ 5 days from onset of influenza-like illness symptoms;
  • Subject (or parent/legal guardian) capable and willing to give informed consent/assent;
  • Subject (or parent/legal guardian) able to read and write English.

排除标准

  • Has undergone treatment with antivirals within the previous 7 days;
  • Has been vaccinated by means of an influenza nasal spray/mist vaccine within the previous 7 days;
  • Recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months;
  • Currently enrolled in another clinical trial or used any investigational device within 90 days preceding informed consent;
  • Has had prior exposure to the Respirio Flu Test or eLab Flu Test.

结局指标

主要结局

Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by eLab Flu Test.

时间窗: Day 1

Establish specificity against a gold standard. Report as a percentage of participants with 96% confidence limits.

Of participants positive for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by eLab Flu Test.

时间窗: Day 1

Establish sensitivity against a gold standard. Report as a percentage of participants with 96% confidence limits.

Of participants positive for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by Respirio Flu Test.

时间窗: Day 1

Establish sensitivity against a gold standard. Report as a percentage of participants with 96% confidence limits.

Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by Respirio Flu Test.

时间窗: Day 1

Establish specificity against a gold standard. Report as a percentage of participants with 96% confidence limits.

次要结局

  • Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by Respirio Flu Test.(Day 1)
  • Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by eLab Flu Test.(Day 1)
  • Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by Respirio Flu Test.(Day 1)
  • Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by eLab Flu Test.(Day 1)
  • Percent of participants who correctly interpret result of Respirio Flu Test.(Day 1)
  • Scores from questionnaire to assess ease of use, comfort and convenience of Respirio Flu Test.(Day 1)

研究者

发起方
Ellume Pty Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验

Validation of the Ellume® Respirio Flu Test and the... | 临床试验